ClinicalTrials.gg
RecruitingNCT05518578Updated Apr 21, 2026

Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy

A Phase 2 interventional study of SPN-817 in Epilepsy and Seizures, Epileptic, sponsored by Supernus Pharmaceuticals, Inc.. Recruiting at 10 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies in Epilepsy with a site in Australia — 14 open to participants now, 20 under way, 10 of them phase 3. Epilepsy · Australia.

Planned enrollment
63rd of 77
60 · median 197
Started
2023
with 5 others
Phase 2
14 of 87
2 open now
Primary completion
2027-12
later than 14 of 19 live
Registered
65th of 87
by date

Among the 87 studies in Epilepsy with a site in Australia, this one is the 63rd largest by planned enrollment of the 77 interventional ones that give a count, is one of 6 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 14 of the 19 other live ones, and was the 65th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

14 of the 87 studies in Epilepsy with a site in Australia are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Epilepsy with a site in Australia, or all of them as a file.
02

Study summary

This study will evaluate the safety and tolerability of SPN-817 in adults with treatment resistant seizures

Read the detailed description

This is a multicenter, three-phase, long-term open-label study assessing the safety and tolerability of SPN-817 (huperzine A, an acetylcholinesterase inhibitor) in adults 18-70 years of age with treatment resistant epilepsy. The Screening period is up to 8 weeks in duration, followed by a Titration Period of 9 weeks and a Maintenance Period of 12 weeks (total Treatment Period of 21 weeks) for eligible participants. The Treatment Period will be followed by an optional Open-Label Extension period which is up to 52 weeks in duration. Schedule A will enroll participants with treatment resistant seizures, and Schedule B will enroll with treatment resistant seizures who will receive SPN-817 along with a concomitant medication to assess pharmacological approaches to managing cholinergic AEs.

03

Conditions studied

  • Epilepsy
  • Seizures, Epileptic

Keywords

  • anti-seizure medication
  • epilepsy
  • focal seizures
  • Phase 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. A diagnosis of treatment resistant epilepsy as adjudicated by the Epilepsy Study Consortium.
  2. Is male or female, aged 18 to ≤ 70 years at screening.
  3. Is able to read, understand, and sign the Form (ICF). If the participant is unable to sign informed consent, a Legally Authorized Representative (LAR) will complete the ICF.
  4. Ability to keep accurate seizure diaries (with the aid of a caregiver as needed).
  5. Weight within the normal or overweight ranges according to accepted values of the Chart (18.0 to 40 kg/m2).
  6. Is able to swallow capsules whole without crushing, chewing, or cutting.
  7. Is willing to adhere to all study procedures and able to attend study visits within the specified time windows.
  8. Failure of at least 2 tolerated, appropriately chosen and adequately dosed ASM drug schedules to achieve sustained seizure freedom.
  9. Taking at least 1 ASM at Screening and Baseline. If following a diet plan along with the ASM, the participant should have been on a stable diet plan for at least 1 month prior to screening (Visit 1). The diet plan should be maintained throughout the duration of the study. Participants on a ketogenic diet will not be permitted to participate in the intense PK group.
  10. At least 4 seizures accepted by the Epilepsy Study Consortium for the secondary outcome (adjudicated as "probable seizures" that are countable) during the 42-day baseline seizure diary period, and no more than a 21-day period that was seizure-free.
  11. A clinical diagnosis of Focal Cortical Dysplasia (FCD) Type I or Type II (approximately n=10) confirmed by:

    1. Likely FCD supported by neuroimaging that has been performed in the last 5 years, or
    2. History of surgical resection of the cortical dysplasia that is histopathologically confirmed in patients who continue to have uncontrolled seizures without a compelling alternate explanation for ongoing seizures.

    Note: The Epilepsy Study Consortium will review to confirm FCD/probable FCD diagnosis.

  12. Be in good general health as per PI's judgment based upon medical history, physical exams, standard 12-lead , and clinical laboratory evaluations obtained during the Screening Period
  13. Be able to comply with and complete all study-specified procedures; enrollment for participants with limited ability to complete self-reported questionnaires or cognitive assessments may be permitted on a case-by-case basis after approval by the MM and Sponsor
  14. Non-pregnant females of (FOCP) who are either in an exclusive same-sex relationship or sexually inactive (abstinent), or if sexually active with a male partner who is biologically capable of having children, must agree to use one of the following acceptable methods beginning 30 days prior to the first dose of SPN-817, throughout the study, and for 30 days following the last dose:

    1. Simultaneous use of male condom and intra-uterine contraceptive device (IUD) placed at least 4 weeks prior to first SPN-817 administration
    2. Surgically sterile male partner (6 months minimum)
    3. Simultaneous use of any male barrier (condom) combined with any female barrier
    4. Established hormonal contraceptive

    Female participants are considered not to be of childbearing potential if they are either (amenorrhea for at least 2 years and serum follicle-stimulating hormone [FSH] level of >40 IU/L) or permanently sterilized (eg, bilateral tubal ligation, hysterectomy, bilateral oophorectomy) for 6 months minimum.

  15. Males must:

    1. Use 2 methods of contraception in combination if his female partner is of childbearing potential; this combination of contraceptive methods must be used from the screening visit to 90 days after the last dose of SPN-817, or
    2. Have been surgically sterilized (6 months minimum) prior to the screening visit
    3. Refrain from donating any sperm from the first administration of SPN-817 until 90 days after the last dose of SPN-817
    4. Males who are in same-sex partner relationships or with those who are not biologically capable of having children are required to use a condom from the first dose through 7 days after the last dose of the SM.

Exclusion criteria

Exclusion Criteria:

  1. Has taken huperzine A within the past year
  2. Is planning to become pregnant or impregnate spouse, not using an acceptable method of (defined as use of double-barrier birth control methods, use of oral contraceptives, or surgical sterilization), pregnant, or nursing.
  3. Participants with Lennox-Gastaut syndrome. Participants should also be excluded in case of nondiagnostic information.
  4. Has non-epileptic events that could be confused by the patient and/or study staff as epileptic seizures.
  5. Has only seizures that are difficult to count; for example, has seizures that are not clinically observable.
  6. Has a history of only seizure clusters, for example, seizure clusters defined as multiple seizures with at least one seizure within 30 minutes of the previous seizure.
  7. Has a history of status epilepticus in the 6 months prior to Screening.
  8. Change in ASM regimen in the last 28 days prior to screening. No changes in ASMs are allowed during the Screening, Titration/Optimization, or Maintenance Period. Changes in ASM regimen (including any diet plan used as an ASM) are allowed during the OLE Period only.
  9. Vagus nerve stimulation (VNS), deep brain stimulation (DBS), responsive neurostimulator system (RNS), or other neurostimulation for epilepsy device implanted or activated \<1 year prior to screening; stimulation parameters that have been stable for \<3 months; or epilepsy surgery \<1 year prior to screening.
  10. Any suicidal behavior or suicidal ideation of type 4 (active suicidal ideation with some intent to act without specific plan) or type 5 (active suicidal ideation with specific plan and intent) based on the C-SSRS in the 2 years before screening; a history of suicide attempt in the last 2 years; or more than 1 lifetime suicide attempt.
  11. Any condition that may impact a patient's ability to follow study procedures or a patient's safety, based on what is known about the pharmacology/toxicology profile of the trial agent(s).
  12. Has a pre-existing medical condition (including an existing progressive or degenerative neurological disorder including brain tumor, active encephalitis, active meningitis or abscess) or takes medications that, in the PI's opinion, could interfere with the patient's suitability for participation in the study.
  13. Has a history or evidence of current significant psychiatric disturbance (e.g., schizophrenia, schizoaffective, or bipolar disorder) that would preclude meaningful participation in the study procedures.
  14. Has a history in the past 2 years or evidence of current alcohol and/or substance use disorder as defined by the 5th edition.
  15. Has had any clinical laboratory abnormalities within the 2 months prior to screening considered of clinical significance by the PI.
  16. Is (HIV)// positive or has a positive urine drug screen (UDS) with the following considerations:

    1. Participants who have a diagnosis of cannabis use disorder (per DSM-5) within 6 months before Screening and have a positive UDS for cannabis at Screening will be excluded. At the discretion of the Sponsor, recreational use of cannabis is allowed and should be kept consistent during the study. Participants must agree to refrain from using cannabis 48 h prior to the study visits.
    2. Cannabis (including cannabidiol [CBD] products) prescribed for a medical condition or used as an ASM is allowed if taken at a stable regimen for at least 28 days prior to Screening. Newly prescribed cannabis treatment and/or a change to the existing regimen is prohibited. When applicable, participants should show proof of their prescription for medical cannabis.
    3. Participants who also test positive for specific medications (benzodiazepines, amphetamines, etc.) must show proof of the prescription and should not be excluded due to a positive UDS if the positive UDS is related to a prescribed medication.
  17. Is on concomitant therapy with non-ASMs that are cholinergic prior to Visit 5
  18. Is currently taking or within the 3 days prior to first administration of SPN-817 has taken over-the-counter supplements containing epigallocatechin gallate (EGCG) such as concentrated green tea extracts or products containing synthetic EGCG, or foods containing > 100 grams of carob powder. Also current or within the 3 days prior the first administration of SPN-817, excessive consumption (> 3 cups per day) of foods or drinks containing EGCG (eg, all green, white, or oolong teas and all black teas) is prohibited.
  19. Has participated in any clinical drug or device study within 4 weeks prior to study entry or within 5 half-lives of the clinical investigational drug, whichever is longer.
  20. cardiologic abnormalities at screening. One repeat assessment is allowed per Investigator discretion.

    Abnormal that is, in the Investigator's opinion, clinically significant including:

    1. Heart rate (HR) \<50 bpm
    2. PR interval >220 ms
    3. QRS interval ≥120 ms
    4. (QT interval corrected for heart rate using Fridericia's method) >450 ms for males and >470 ms for female participants
    5. Second or third-degree atrioventricular block
    6. Any rhythm, other than sinus rhythm, that is interpreted by the Investigator to be clinically significant
  21. Has abnormal renal function as demonstrated by estimated (eGFR) of \<60 mL/min according to the eGFR Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation at screening.
  22. Clinically significant vital signs abnormalities (systolic blood pressure \<90 or >140 mmHg, diastolic blood pressure \<50 or >90 mmHg, or HR \<50 or >100 bpm) at screening.
  23. Participant has had >2 allergic reactions to an ASM or 1 serious reaction to an ASM.
  24. Participants who donated 50-499 mL of blood within 30 days or >499 mL within 56 days prior to Day 1 administration or have \<128 g/L (male) or \<115 g/L (female) and hematocrit \<0.37 L/L (males) or \<0.32 L/L (female) at screening. Following screening and throughout the study, participants should not donate blood.
  25. Any reason which, in the opinion of the PI, would prevent the participant from participating in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Open-Label Treatment

    0.25 mg to 4 mg SPN-817 taken orally twice daily

    Drug: SPN-817

Interventions

  • oral capsule

    Also known as: (-)-Huperzine A extended-release

06

What researchers measure

Primary outcomes

  1. Effects of SPN-817 on safety and tolerability

    The incidence of adverse events.

    Time frame: 72 weeks

Secondary outcomes

  1. Effect of SPN-817 on the motor seizure frequency

    Percent change from baseline in quantifiable motor seizure frequency per 28 days during treatment in the combined Titration/Optimization and Maintenance Periods, in the Maintenance Period, and in the combined Maintenance and Open-Label Extension Periods. A "quantifiable motor seizure" is defined as a seizure adjudicated as probable and countable by the Epilepsy Study Consortium, Inc. (ESCI).

    Time frame: 72 weeks

  2. Effect of SPN-817 on the motor seizure frequency treatment response rate

    The 30%, 50% and 75% motor seizure frequency treatment response rate during treatment in the combined Titration/Optimization and Maintenance Periods and in the Maintenance Period. The 30%, 50% or 75% seizure frequency treatment response rate is defined as the percent of subjects who have a ≥30%, ≥50%, or ≥75% reduction, respectively, in the change from baseline quantifiable motor seizure frequency. A "quantifiable motor seizure" is defined as a seizure adjudicated as probable and countable by the Epilepsy Study Consortium, Inc. (ESCI).

    Time frame: 20 weeks

  3. Effect of SPN-817 on incidence of motor seizure-free days.

    Change from Baseline in the percentage of quantifiable motor seizure-free days per 28 days during treatment. A "quantifiable motor seizure" is defined as a seizure adjudicated as probable and countable by the Epilepsy Study Consortium, Inc. (ESCI).

    Time frame: 72 weeks

  4. Effect of SPN-817 on the Clinical Global Impression - Improvement (CGI-I) scale

    CGI-I score by visit during treatment.

    Time frame: 72 weeks

  5. Effect of SPN-817 on the Clinical Global Impression - Severity (CGI-S) scale

    Change from Baseline in the CGI-S score by visit during treatment.

    Time frame: 72 weeks

  6. Effect of SPN-817 on the Quality of Life in Epilepsy (QOLIE-31-P; v2.0) questionnaire

    Change from Baseline in QOLIE-31-P score by visit during treatment.

    Time frame: 72 weeks

  7. Effect of SPN-817 on the Seizure Related Disability Assessment Scale (SERDAS) scale

    Change from Baseline in SERDAS score by visit during treatment.

    Time frame: 72 weeks

07

Study locations

8 of 10 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Dec 2027, 58 months after the start.

Of 45 industry-sponsored phase 2 interventional studies under Epilepsy, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 58 months is above that.

Counting every sponsor, half of 66 studies reached it within 23 months; a quarter within 14 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 23, 2022
First posted
Aug 26, 2022
StartActual
Feb 7, 2023
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2027
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05518578
Responsible party
Sponsor
First posted
Aug 26, 2022
Start date
Feb 7, 2023
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Apr 21, 2026

Study contacts

Supernus Clinical Trials
Contact
clinicaltrials@supernus.com
240-403-5838
Navid Saiedi, MS
Contact
nsaeidi@supernus.com
240-403-5328
Maciej Gasior, MD, PhD
study director · Supernus Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SPN-817

Start the discussion